Brought to you by 
EnVivo gets license to MethylGene's HDAC inhibitors
06 Apr 2009
Executive Summary
EnVivo Pharmaceuticals (CNS disorders) has exercised its option to exclusively use MethylGene's (cancer and infectious diseases) isotypic selective small-molecule histone deacetylase (HDAC) inhibitors to create therapeutics for neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EnVivo gets license to MethylGene's HDAC inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice